166 related articles for article (PubMed ID: 31268632)
1. Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions.
Storelli F; Desmeules J; Daali Y
CPT Pharmacometrics Syst Pharmacol; 2019 Aug; 8(8):567-576. PubMed ID: 31268632
[TBL] [Abstract][Full Text] [Related]
2. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine.
Cho CK; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 May; 47(5):481-504. PubMed ID: 38664354
[TBL] [Abstract][Full Text] [Related]
3. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.
Min JS; Kim D; Park JB; Heo H; Bae SH; Seo JH; Oh E; Bae SK
Drug Des Devel Ther; 2016; 10():2959-2972. PubMed ID: 27695293
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.
Storelli F; Matthey A; Lenglet S; Thomas A; Desmeules J; Daali Y
Clin Pharmacol Ther; 2018 Jul; 104(1):148-157. PubMed ID: 28940476
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes.
Xu M; Zheng L; Zeng J; Xu W; Jiang X; Wang L
Pharmacotherapy; 2021 Mar; 41(3):277-290. PubMed ID: 33316842
[TBL] [Abstract][Full Text] [Related]
6. A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.
Ke AB; Nallani SC; Zhao P; Rostami-Hodjegan A; Isoherranen N; Unadkat JD
Drug Metab Dispos; 2013 Apr; 41(4):801-13. PubMed ID: 23355638
[TBL] [Abstract][Full Text] [Related]
7. Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes.
Storelli F; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):170-180. PubMed ID: 30192434
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.
Huang W; Nakano M; Sager J; Ragueneau-Majlessi I; Isoherranen N
Drug Metab Dispos; 2017 Nov; 45(11):1156-1165. PubMed ID: 28860113
[TBL] [Abstract][Full Text] [Related]
9. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers.
Wilner KD; Demattos SB; Anziano RJ; Apseloff G; Gerber N
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):43S-47S. PubMed ID: 10771453
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.
Chen R; Wang H; Shi J; Shen K; Hu P
Eur J Clin Pharmacol; 2015 Jul; 71(7):835-41. PubMed ID: 25967538
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction.
Monte AA; West K; McDaniel KT; Flaten HK; Saben J; Shelton S; Abdelmawla F; Bushman LR; Williamson K; Abbott D; Anderson PL
Clin Pharmacol Ther; 2018 Nov; 104(5):933-939. PubMed ID: 29882961
[TBL] [Abstract][Full Text] [Related]
12. Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups.
Rüdesheim S; Selzer D; Fuhr U; Schwab M; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):494-511. PubMed ID: 35257505
[TBL] [Abstract][Full Text] [Related]
13. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.
Schoedel KA; Pope LE; Sellers EM
Clin Drug Investig; 2012 Mar; 32(3):157-69. PubMed ID: 22283559
[TBL] [Abstract][Full Text] [Related]
14. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
Jung EH; Lee YJ; Kim DH; Kang P; Lim CW; Cho CK; Jang CG; Lee SY; Bae JW
Arch Pharm Res; 2020 Dec; 43(12):1356-1363. PubMed ID: 33245517
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.
Lim KS; Cho JY; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Shin SG; Yu KS
Br J Clin Pharmacol; 2008 Nov; 66(5):660-6. PubMed ID: 18754843
[TBL] [Abstract][Full Text] [Related]
16. Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.
Nishimura M; Ueda M; Saruwatari J; Nakashima H; Ogusu N; Aoki A; Tsuchimine S; Matsuda K; Iwashita K; Ono T; Oniki K; Shimoda K; Yasui-Furukori N
Pharmacogenet Genomics; 2016 Sep; 26(9):403-13. PubMed ID: 27187662
[TBL] [Abstract][Full Text] [Related]
17. Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6.
Chen R; Rostami-Hodjegan A; Wang H; Berk D; Shi J; Hu P
Eur J Pharm Sci; 2016 Sep; 92():131-6. PubMed ID: 27412587
[TBL] [Abstract][Full Text] [Related]
18. Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.
Marsousi N; Desmeules JA; Rudaz S; Daali Y
Biopharm Drug Dispos; 2018 Jan; 39(1):3-17. PubMed ID: 28960401
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.
Chen Y; Zhou D; Tang W; Zhou W; Al-Huniti N; Masson E
J Clin Pharmacol; 2018 Apr; 58(4):485-493. PubMed ID: 29193123
[TBL] [Abstract][Full Text] [Related]
20. Inter-individual variability of in vivo CYP2D6 activity in different genotypes.
Chiba K; Kato M; Ito T; Suwa T; Sugiyama Y
Drug Metab Pharmacokinet; 2012; 27(4):405-13. PubMed ID: 22277677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
